Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Retinopathy | 11 | 2018 | 72 | 1.030 |
Why?
|
| Visual Acuity | 12 | 2018 | 76 | 0.930 |
Why?
|
| Lens Subluxation | 3 | 2006 | 4 | 0.640 |
Why?
|
| Macular Edema | 7 | 2018 | 17 | 0.640 |
Why?
|
| Vitreous Body | 4 | 2011 | 10 | 0.480 |
Why?
|
| Eye Injuries | 2 | 2006 | 15 | 0.420 |
Why?
|
| Cataract Extraction | 4 | 2014 | 11 | 0.410 |
Why?
|
| Eye Infections, Fungal | 1 | 2013 | 1 | 0.390 |
Why?
|
| Candida albicans | 1 | 2013 | 13 | 0.390 |
Why?
|
| Endophthalmitis | 1 | 2013 | 8 | 0.380 |
Why?
|
| Scleral Buckling | 1 | 2011 | 4 | 0.340 |
Why?
|
| Eye Diseases | 1 | 2011 | 4 | 0.340 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2017 | 1438 | 0.340 |
Why?
|
| Foreign-Body Migration | 1 | 2011 | 10 | 0.340 |
Why?
|
| Sutures | 1 | 2011 | 19 | 0.340 |
Why?
|
| Suture Techniques | 1 | 2011 | 60 | 0.330 |
Why?
|
| Macular Degeneration | 1 | 2009 | 25 | 0.290 |
Why?
|
| Methotrexate | 1 | 2009 | 70 | 0.290 |
Why?
|
| Laser Coagulation | 4 | 2018 | 13 | 0.270 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 248 | 0.260 |
Why?
|
| Hypoglycemic Agents | 3 | 2017 | 186 | 0.260 |
Why?
|
| Retinal Diseases | 2 | 2006 | 25 | 0.240 |
Why?
|
| Play and Playthings | 1 | 2006 | 6 | 0.240 |
Why?
|
| Nematode Infections | 1 | 2005 | 2 | 0.230 |
Why?
|
| Eye Infections, Parasitic | 1 | 2005 | 2 | 0.230 |
Why?
|
| Retinal Vein Occlusion | 1 | 2005 | 2 | 0.230 |
Why?
|
| Vision Disorders | 1 | 2004 | 23 | 0.210 |
Why?
|
| Thiazolidinediones | 2 | 2017 | 46 | 0.210 |
Why?
|
| Vitrectomy | 1 | 2004 | 10 | 0.210 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2018 | 38 | 0.200 |
Why?
|
| Humans | 22 | 2018 | 32286 | 0.190 |
Why?
|
| Lens, Crystalline | 1 | 2002 | 2 | 0.190 |
Why?
|
| Cataract | 1 | 2002 | 5 | 0.190 |
Why?
|
| Contusions | 1 | 2002 | 41 | 0.180 |
Why?
|
| Male | 15 | 2018 | 19448 | 0.180 |
Why?
|
| Postoperative Complications | 1 | 2004 | 818 | 0.140 |
Why?
|
| Fluocinolone Acetonide | 1 | 2018 | 5 | 0.140 |
Why?
|
| Female | 13 | 2018 | 19955 | 0.140 |
Why?
|
| Middle Aged | 12 | 2018 | 11848 | 0.130 |
Why?
|
| Prognosis | 4 | 2014 | 1529 | 0.120 |
Why?
|
| Hyperglycemia | 2 | 2014 | 85 | 0.120 |
Why?
|
| Aged | 8 | 2014 | 10259 | 0.120 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 2238 | 0.120 |
Why?
|
| Diabetic Angiopathies | 2 | 2014 | 150 | 0.110 |
Why?
|
| Lasers, Dye | 1 | 2013 | 1 | 0.100 |
Why?
|
| Triamcinolone Acetonide | 1 | 2013 | 4 | 0.100 |
Why?
|
| Retrospective Studies | 4 | 2010 | 3612 | 0.100 |
Why?
|
| Photography | 1 | 2013 | 42 | 0.100 |
Why?
|
| Antifungal Agents | 1 | 2013 | 44 | 0.090 |
Why?
|
| Adult | 5 | 2006 | 9263 | 0.090 |
Why?
|
| Diabetic Nephropathies | 1 | 2014 | 223 | 0.090 |
Why?
|
| Infant, Premature | 1 | 2013 | 74 | 0.090 |
Why?
|
| Fluorescein Angiography | 2 | 2009 | 18 | 0.090 |
Why?
|
| Injections | 2 | 2009 | 72 | 0.090 |
Why?
|
| Cardiovascular Diseases | 3 | 2014 | 1159 | 0.090 |
Why?
|
| Tomography, Optical Coherence | 2 | 2009 | 47 | 0.090 |
Why?
|
| Retinal Detachment | 1 | 2011 | 10 | 0.090 |
Why?
|
| Penicillin G Benzathine | 1 | 2011 | 1 | 0.090 |
Why?
|
| Choroid Diseases | 1 | 2011 | 1 | 0.090 |
Why?
|
| Granuloma | 1 | 2011 | 14 | 0.080 |
Why?
|
| Syphilis | 1 | 2011 | 10 | 0.080 |
Why?
|
| Infant, Newborn | 1 | 2013 | 666 | 0.080 |
Why?
|
| Choroid Neoplasms | 1 | 2010 | 4 | 0.080 |
Why?
|
| Iodine Radioisotopes | 1 | 2010 | 22 | 0.080 |
Why?
|
| Infant | 1 | 2013 | 1010 | 0.080 |
Why?
|
| Brachytherapy | 1 | 2010 | 29 | 0.080 |
Why?
|
| Exudates and Transudates | 1 | 2009 | 2 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 3899 | 0.070 |
Why?
|
| Drug Resistance | 1 | 2009 | 42 | 0.070 |
Why?
|
| Melanoma | 1 | 2010 | 166 | 0.070 |
Why?
|
| Disease Progression | 3 | 2017 | 591 | 0.070 |
Why?
|
| Glucocorticoids | 3 | 2018 | 146 | 0.070 |
Why?
|
| Child | 2 | 2006 | 2432 | 0.070 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 365 | 0.060 |
Why?
|
| Incidence | 3 | 2017 | 1243 | 0.060 |
Why?
|
| Adolescent | 2 | 2006 | 3519 | 0.060 |
Why?
|
| Retinal Vessels | 1 | 2006 | 27 | 0.060 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2006 | 2 | 0.060 |
Why?
|
| Rupture | 1 | 2006 | 33 | 0.060 |
Why?
|
| Retina | 2 | 2007 | 85 | 0.060 |
Why?
|
| Consumer Product Safety | 1 | 2006 | 2 | 0.060 |
Why?
|
| Blindness | 1 | 2006 | 13 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2006 | 55 | 0.060 |
Why?
|
| Product Labeling | 1 | 2006 | 19 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 245 | 0.060 |
Why?
|
| Nematoda | 1 | 2005 | 2 | 0.060 |
Why?
|
| Papilledema | 1 | 2005 | 13 | 0.060 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 2 | 2014 | 9 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2013 | 550 | 0.050 |
Why?
|
| Risk Factors | 2 | 2014 | 3937 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 427 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2017 | 567 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 854 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 1485 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 760 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2017 | 484 | 0.030 |
Why?
|
| Decision Trees | 1 | 2014 | 30 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 169 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 1840 | 0.020 |
Why?
|
| Fundus Oculi | 1 | 2013 | 13 | 0.020 |
Why?
|
| Animals | 1 | 2005 | 8197 | 0.020 |
Why?
|
| Observer Variation | 1 | 2013 | 96 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 556 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 3409 | 0.020 |
Why?
|
| Simvastatin | 1 | 2010 | 26 | 0.020 |
Why?
|
| Eye Enucleation | 1 | 2010 | 5 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2010 | 62 | 0.020 |
Why?
|
| Ligands | 1 | 2010 | 90 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2010 | 106 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2010 | 60 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2010 | 170 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 293 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 501 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 322 | 0.020 |
Why?
|
| Cause of Death | 1 | 2010 | 236 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 471 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 455 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 325 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 113 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2007 | 555 | 0.010 |
Why?
|
| Research Design | 1 | 2007 | 316 | 0.010 |
Why?
|
| Time Factors | 1 | 2010 | 2203 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 545 | 0.010 |
Why?
|
| Hypertension | 1 | 2010 | 983 | 0.010 |
Why?
|